AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
NTR
ACCE-researched

Nutrien Ltd. Common Shares (NTR) fair value

Basic Materials · Agricultural Inputs · NYSE · United States
$69.74+0.94%
Market cap $33.3BNext earnings 2026-11-04Updated Oct 19, 2026
Add earnings to calendarGoogle
Our verdict
Trades 6% below our fair value
Price
$69.74
Model fair valueConfidence: good
$73.85
Model range
$63.27 to $81.65
Fair value $73.85
Price $69.74
4 models fit Nutrien Ltd. Common Shares and they agree: 4 of 4 land within 15% of the average.
Two or more of our models back this value.
Near fair value(i)Silver67
Valued as a cyclical company: P/E comparison, EV/EBITDA comparison, Discounted cash flow, and Graham number.
ACCE opinionNutrien Ltd. Common Shares (NTR)
Fair value (4 models)
$73.85
ACCE price target
$78.00
Rating
Fairly valued
Horizon
12 months
Fair value published on 19 Oct 2026, 19:04 CEST; previously $89.73 since 15 Oct 2026, 00:00 CEST.
ACCE price target published on 21 Sept 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 19:04 CEST.
Price used: $69.74 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
5.6% below
+5.9% to fair value
ACCE score
60
out of 100
Analysts
60% buy
25 covering
P/E
14.1x
forward 14.7x
1-year return
+20.6%
Dividend yield
3.17%

Nutrien Ltd. Common Shares in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Nutrien is the world's largest producer of potash and a major supplier of nitrogen and phosphate fertilizers, sold through its own retail network of farm supply stores in North America, Brazil and Australia. Its structural advantage is scale in potash, a mineral with a concentrated supply base, plus a retail arm that gives it direct access to growers and a way to capture margin beyond the commodity itself. Growth is modest, with revenue up 4.0%, so the case rests more on earnings power through the fertilizer cycle than on top-line expansion. At 13.8 times trailing earnings and 13.5 times forward, the stock is priced without a heroic recovery assumption, and a 17.5% operating margin and 32.1% gross margin show the business still earns solid returns on its assets. The score of 58 out of 100 and a 9.4% return on equity say this is a cyclical name that needs a view on fertilizer prices and farm income before it earns a position, which is reason enough to open the model and check the potash price deck.

AI-assisted·How I use AIWritten Oct 13, 2026
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
  • high
    ACCE score collapse
    Score fell 12 points in 90 days (70 to 58). Growth pillar dropped to 40/100, signalling deceleration concerns despite +82.9% QoQ bounce.
  • moderate
    Earnings growth stalling
    YoY earnings growth of +1.2% lags revenue growth of +4.0%. Margin compression risk if input costs or competition intensify.
  • moderate
    Quality score weakness
    Q pillar at 63/100 suggests balance sheet or cash conversion concerns. FCF of $2.0B is solid, but score implies operational or working capital headwinds.

AI research notes

AI-assisted·How I use AIWritten Oct 11, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Company generated $2.0B in free cash flow last 12 months, yielding 6.3%, while returning capital via 1.6% annual share buybacks.
Why it could disappoint
  • Return on invested capital of 4.9% trails the 5.2% risk-free rate, meaning the company destroys value on new capital deployment.
  • Implied cash flow growth of 2.9% over the next five years falls short of the 5.2% historical average, suggesting deceleration ahead.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where NTR's valuation models land
Price
$69.74
Model fair value
$73.85
Model range
$63.27 to $81.65
Fair value $73.85
Price $69.74
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish60% buy · 25 covering analysts
● Strong buy 8● Buy 7● Hold 8● Sell 0● Strong sell 2
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
-2.1%
1 month
-7.2%
3 months
+2.4%
6 months
-2.6%
YTD
+13.0%
1 year
+20.6%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
19 Oct 2026, 19:04 CESTRatingFairly valuedfirst publication$71.26
19 Oct 2026, 19:04 CESTFair value$73.85$89.73$71.26
15 Oct 2026, 00:00 CESTFair value$89.73$93.75$69.68
11 Oct 2026, 00:00 CESTFair value$93.75$87.61$67.48
5 Oct 2026, 00:00 CESTFair value$87.61$88.66$70.06
28 Sept 2026, 00:00 CESTFair value$88.66$90.24$72.23
26 Sept 2026, 00:00 CESTFair value$90.24$91.26$73.96
21 Sept 2026, 00:00 CESTACCE price target$78.00first publication$77.09
14 Sept 2026, 00:00 CESTFair value$91.26$93.97$78.45
26 Aug 2026, 00:00 CESTFair value$93.97$95.19$73.80

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full NTR page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth40Value83Quality63Momentum54Total60
Valuation
Trailing P/E
14.1x
Forward P/E
14.7x
PEG
1.98
P/B
1.39x
EV / Revenue
1.7x
Book value/sh
$54.16
Enterprise value
$47.9B
Profitability
ROE
9.4%
FCF yield
6.18%
ROIC
4.9%
Health and risk
Debt / equity
0.51
Dividend yield
3.17%
Beta
1.13

Price

+19.9% · 1Y

Ask anything about NTR

Answered from Nutrien Ltd. Common Shares fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 40% of peers
low 7.5x14.1xhigh 19.9x
ROEbetter than 67% of peers
low -5%9%high 30%
Div yieldbetter than 17% of peers
low 1.7%3.2%high 5.6%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
NTR Nutrien Ltd. Common Shares$69.74$746% below14.1x9.4%6360
NTR.TO NutrienC$96.70C$1047% below14.3x9.4%6360
CF CF Industries Holdings Inc. Common Stock$118.56$14217% below8.6x29.9%8785
YAR.OL Yara Internationalkr 399.40kr 56429% below7.5x17.9%6466
CTVA Corteva Inc. Common Stock $12.86$2752% below7.7x4.3%5538
ICL ICL Group Ltd. Ordinary Shares$4.71$625% below19.9x5.6%5656
MOS Mosaic Company (The) Common Stock$17.27$3449% below--5.1%2734

Sector report card

Where NTR ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Oct 15, 2026
    Nutrien Announces Release Dates for Third Quarter 2026 Results and Conference Call
  • Business Wire•Oct 5, 2026
    Nutrien Provides Update on Trinidad Nitrogen Operations
  • GlobeNewswire•Sep 30, 2026
    Controlled-release Fertilizers Market to Reach USD 3.61 Billion by 2031 at 6.1% CAGR
5 more press releases · full archive on Investor+.INVESTOR
22 filings of 38
October 2026
Oct 5
6-KForeign current reportPeriod 2026-10-05
View on SEC →
August 2026
Aug 6
6-KForeign current reportPeriod 2026-08-05
View on SEC →
Aug 5
6-KForeign current reportPeriod 2026-08-05
View on SEC →
19 more filings + AI summaries on Investor+.INVESTOR